ENTPD1 and sarcoma: Several CD39 inhibitors, including ARL67156 and POM-1, have shown efficacy in animal models of follicular lymphoma, sarcoma, or murine melanoma, resulting in a partial overcome of T-cell hypo-responsiveness to stimulation (162), increased therapeutic response to chemotherapeutic agents (183), or inhibition of tumor growth (184), respectively.